ANI Pharmaceuticals Announces Buyout of Royalty Obligation for ILUVIEN® and YUTIQ®

Core Points - ANI Pharmaceuticals, Inc. has completed the buyout of its 3.125% perpetual royalty obligation to SWK Funding LLC for a one-time payment of $17.25 million, eliminating future royalty payments on net revenues of ILUVIEN and YUTIQ starting January 1, 2025 [1][2] - The buyout enhances ANI's financial flexibility and supports the growth of its Retina portfolio, aligning with the company's mission of "Serving Patients, Improving Lives" [2] Company Overview - ANI Pharmaceuticals is a diversified biopharmaceutical company focused on developing, manufacturing, and commercializing innovative therapeutics across various therapeutic areas, including ophthalmology, rheumatology, nephrology, neurology, and pulmonology [2] - The company aims for sustainable growth through its Rare Disease business, Generics business, and Brands business [2]